What is Sinovac Biotech Financial Strength?
Sinovac Biotech has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Sinovac Biotech did not have earnings to cover the interest expense.
Sinovac Biotech's debt to revenue ratio for the quarter that ended in Jun. 2023 was 0.94.
As of today, Sinovac Biotech's Altman Z-Score is 1.96.
Competitive Comparison of Sinovac Biotech's Financial Strength
For the Biotechnology subindustry, Sinovac Biotech's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Financial Strength distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's Financial Strength falls into.
Sinovac Biotech Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Sinovac Biotech's Interest Expense for the
months ended in Jun. 2023 was $-0.3 Mil. Its Operating Income for the
months ended in Jun. 2023 was $-430.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $51.9 Mil.
Sinovac Biotech's Interest Coverage for the quarter that ended in Jun. 2023 is
| Sinovac Biotech did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Sinovac Biotech's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Sinovac Biotech has a Z-score of 1.96, indicating it is in Grey Zones. This implies that Sinovac Biotech is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 1.96 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinovac Biotech (Sinovac Biotech) Business Description
Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
| Lily Wang |
director, 10 percent owner, officer: Chief Financial Officer |
300 MURCHISON DR., MILLBRAE CA 94030 |
| Ifg Investments Services Inc |
10 percent owner |
PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000 |
| Yin Weidong |
director, 10 percent owner, officer: President and CEO |
|
| Terry G Bowering |
director, 10 percent owner, officer: President, CEO |
10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SVA has been successfully added to your